Breaking News

Hoth Therapeutics Acquires New Patent Applications

Enhances its intellectual property portfolio.

Hoth Therapeutics Inc., a patient-focused biopharmaceutical company, has enhanced its intellectual property portfolio by acquiring and expanding patent applications to its therapeutic pipeline.

These newly secured patents reflect Hoth’s commitment to pioneering treatments that address unmet medical needs, with a focus on enhancing therapeutic efficacy and broadening applications across various disease areas.

“Our expanding intellectual property portfolio supports Hoth’s position as a leader in innovative drug development,” said Robb Knie, CEO of Hoth Therapeutics. “These provisional patent applications reinforce our proprietary approaches and our mission to deliver breakthrough therapies that improve patients’ lives.”

Hoth Therapeutics continues to invest in research and development strategies, ensuring the protection and growth of its proprietary technologies. The company remains dedicated to advancing its pipeline and delivering impactful healthcare solutions.

More Hoth Therapeutics News

In August, Hoth Therapeutics entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics